Streetbeat News

Regulatory

FOXO

FOXO Technologies' Interim CFO outlines the company's progress and future plans, including recent acquisitions and a new patent. The company aims to generate over $50M in annual revenue within 12-24 months by expanding its epigenetic technology and healthcare services. FOXO is addressing NYSE listing requirements and seeking new capital for growth.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:36 pm

MAIA

MAIA Biotechnology announced that its abstract on second-generation THIO prodrugs has been accepted for presentation at the ENA 2024 Symposium. The company will present preclinical study results of its new telomere-targeting molecules, MAIA-2021-20 and MAIA-2022-12.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:34 pm

OKLO

The Department of Energy (DOE) has approved the Conceptual Safety Design Report for Oklo's Aurora Fuel Fabrication Facility. This approval advances Oklo's plans to utilize recovered nuclear material for its first commercial powerhouse.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:27 pm

ARDX

Ardelyx, Inc. will present additional data on XPHOZAH, a first-in-class phosphate absorption inhibitor for adults with chronic kidney disease on dialysis, at the American Society of Nephrology's Kidney Week in October 2024.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:26 pm

MNPR

Monopar Therapeutics Inc. has filed a provisional patent for new therapeutic radiopharmaceuticals, enhancing their intellectual property portfolio. The patent covers a family of linkers that improve stability and biodistribution of radiopharmaceuticals, including their uPAR targeting antibody MNPR-101.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:25 pm

PRME

Prime Medicine, Inc. (NASDAQ:PRME) is set to present new preclinical data, including in vivo data for Wilson's Disease, at upcoming scientific meetings. The company plans to start IND-enabling activities for its Wilson's Disease program in Q4 2024, with an IND or CTA filing expected in the first half of 2026. These developments highlight the progress in Prime Medicine's Prime Editing pipeline and platform.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:22 pm

BIVI

BioVie Inc. has received a Notice of Allowance from the Japan Patent Office for its novel liquid formulation of terlipressin, which is stable at room temperature for up to 24 months. This patent adds to BioVie's existing patents in the US, India, and Chile, and supports the development of a patient-centric treatment for cirrhosis and ascites.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:21 pm

IMRX

Immuneering has been granted FDA Orphan Drug Designation for its drug IMM-1-104, aimed at treating pancreatic cancer. This designation can provide benefits such as tax credits, user fee waivers, and market exclusivity, potentially boosting the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:11 pm

BABA

JD

LI

NIO

US-listed Chinese stocks, including Alibaba, Nio, JD.Com, and Li Auto, saw significant declines as investors await clarity on China's fiscal stimulus plan. Concerns over the effectiveness of China's economic measures have led to skepticism in the market.

Portfolio Pulse from Pooja Rajkumari

October 15, 2024 | 12:11 pm

ALZN

Alzamend Neuro, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:09 pm